Did a gadolinium-based MRI contrast dye cause side effects such as nephrogenic systemic fibrosis?
Please complete the form below to discuss legal options. In October 2008, the Division of Nephrology, Vanderbilt University Medical Center in Nashville, TN, discovered a link between gadolinium based contrast dyes and the development of nephrogenic systemic fibrosis–a rare but serious skin and joint disease–in patients with chronic kidney disease or acute kidney injury. If you developed side effects such as NSF, you have a right to seek legal remedy with a lawsuit. Many research studies suggest a strong link between using gadolinium MRI contrast agents and developing nephrogenic systemic fibrosis in patients with renal disease. Research data also suggest that the risk of nephrogenic systemic fibrosis depends on the degree of renal dysfunction, dose of contrast agent, gadolinium contrast agent stability and severity of concomitant illness. In light of this risk, health care professionals have been advised to use the gadolinium contrast dyes sparingly in patients with kidney problems,
Related Questions
- Can magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) scans be performed without using gadolinium-based contrast agents?
- Has Nephrogenic Systemic Fibrosis (NSF) been reported with all of the U.S.-approved gadolinium-based contrast agents?
- Did a gadolinium-based MRI contrast dye cause side effects such as nephrogenic systemic fibrosis?
